Blood Pressure-Lowering Efficacy of the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone: A Factorial Study

Journal of Clinical Hypertension

Volumn 14, Issue 5, 2012, Pages 284-292

  Sica, Domenic ^a   Bakris, George L ^b   White, William B ^c   Weber, Michael A ^d   Cushman, William C ^e   Huang, Patrick ^f   Roberts, Andrew ^f   Kupfer, Stuart ^f  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^f TAKEDA PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; AZILSARTAN MEDOXOMIL; AZILSARTAN MEDOXOMIL PLUS CHLORTHALIDONE; CHLORTALIDONE; CREATININE; UNCLASSIFIED DRUG;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BLOOD PRESSURE; CHLORTHALIDONE; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OXADIAZOLES; TREATMENT OUTCOME;

EID: 84860346395     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2012.00616.x     Document Type: Article

References (27)

1. Cushman WC, Ford CE, Einhorn PT, et al. Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JClin Hypertens (Greenwich). 2008;10:751-760.
2. Sica DA. Rationale for the use of fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002;62:2761-2788.
3. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
4. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2007;16:135-232.
5. Bramlage P. Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension. Expert Opin Pharmacother. 2009;10:1755-1767.
6. Khanna A, Lefkowitz L, White WB. Evaluation of recent fixed-dose combination therapies in the management of hypertension. Curr Opin Nephrol Hypertens. 2008;17:477-483.
7. Trenkwalder P, Ulmer HJ, Weidinger G, Handrock R. Efficacy and safety of valsartan 160mg/hydrochlorothiazide 25mg combination in patients with hypertension not adequately controlled by valsartan 160mg/hydrochlorothiazide 12.5mg. Clin Drug Investig. 2004;24:593-602.
8. Lacourcière Y, Poirier L, Lefebvre J, et al. Increasing the doses of both diuretics and angiotensin receptor blockers is beneficial in subjects with uncontrolled systolic hypertension. Can J Cardiol. 2010;26:313-319.
9. Karlson BW, Zetterstrand S, Olofsson B, Elmfeldt D. A dose-response analysis of candesartan-hydrochlorothiazide combination therapy in patients with hypertension. Blood Press. 2009;18:149-156.
10. Freis ED, Reda DJ, Materson BJ. Volume (weight) loss and blood pressure response following thiazide diuretics. Hypertension. 1988;12:244-250.
11. Sica DA. Chlorthalidone - has it always been the best thiazide-type diuretic? Hypertension. 2006;47:321-322.
12. Bakris GL, Sica D, Weber M, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011;13:81-88.
13. White WB, Weber MA, Sica D, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011;57:413-420.
14. Sica D, White WB, Weber MA, et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2011;26:185-193.
15. O'Brien E, Pickering T, Asmar R, et al. Working Group on Blood Pressure Monitoring of the European Society of Hypertension International Protocol for validation of blood pressure measuring devices in adults. Blood Press Monit. 2002;7:3-17.
16. Graves JW, Tibor M, Murtagh B, et al. The Accoson Greenlight 300, the first non-automated mercury-free blood pressure measurement device to pass the International Protocol for blood pressure measuring devices in adults. Blood Press Monit. 2004;9:13-17.
17. Levey AS, Bosch JP, Lewis JB, et al. Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.
18. Schoolwerth A, Sica DA, Ballermann BJ, et al, for the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation. 2001;104:1985-1991.
19. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-1252.
20. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
21. Multiple Risk Factor Intervention Trial Research Group. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990;82:1616-1628.
22. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
23. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534-2544.
24. Riess W, Dubach UC, Burckhardt D, et al. Pharmacokinetic studies with chlorthalidone (Hygroton) in man. Eur J Clin Pharmacol. 1977;12:375-382.
25. Chen TM, Chiou WL. Large differences in the biological half-life and volume of distribution of hydrochlorothiazide in normal subjects from eleven studies. Correlation with their last blood sampling times. Int J Clin Pharmacol Ther Toxicol. 1992;30:34-37.
26. Rump LC, Girerd X, Sellin L, Stegbauer J. Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension. J Hum Hypertens. 2011;25:565-574.
27. Cushman WC, Sica DA, Bakris GL, et al. Comparison of the antihypertensive efficacy and safety of azilsartan medoxomil/chlorthalidone with olmesartan/hydrochlorothiazide fixed-dose combinations in Stage 2 systolic hypertension. J Clin Hypertens. 2011;13(suppl 1):A81.